Constitutive activation of nuclear factor-κB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines

Cancer Science

Volumn 100, Issue 9, 2009, Pages 1668-1674

  Yamaguchi, Noritaka ^a,b   Ito, Taku ^a   Azuma, Sakura ^b   Ito, Emi ^c   Honma, Reiko ^c   Yanagisawa, Yuka ^c   Nishikawa, Akira ^c,d   Kawamura, Mika ^c,e   Imai, Jun ichi ^c   Watanabe, Shinya ^c   Semba, Kentaro ^b   Inoue, Jun ichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d NIPPON GENE Co Ltd   (Japan)

^e Medicrome   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NF KAPPA B KINASE; NF-KAPPA B KINASE; PROGESTERONE RECEPTOR; PROTEIN SERINE THREONINE KINASE;

ARTICLE; BASAL CELL CARCINOMA; BREAST TUMOR; CELL PROLIFERATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 70149106789     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01228.x     Document Type: Article

References (35)

1. Smalley M, Ashworth A. Stem cells and breast cancer: a field in transit. Nat Rev Cancer 2003; 3: 832-844.
2. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007; 7: 659-672.
3. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review.J Clin Oncol 2008; 26: 2568-81.
4. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004; 18: 2195-2224.
5. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-436.
6. Inoue J, Gohda J, Akiyama T et al. NF-κB activation in development and progression of cancer. Cancer Sci 2007; 98: 268-274.
7. Nakshatri H, Bhat-Nakshatri P, Martin DA et al. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3629-3639.
8. Biswas DK, Shi Q, Baily S et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004; 101: 10137-10142.
9. Peters RT, Liao SM, Maniatis T. IKKε is part of a novel PMA-inducible IκB kinase complex. Mol Cell 2000; 5: 513-522.
10. Boehm JS, Zhao JJ, Yao J et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-1079.
11. Ito E, Honma R, Yanagisawa Y et al. Novel clusters of highly expressed genes accompany genomic amplification in breast cancers. FEBS Lett 2007; 581: 3909-3914.
12. Horie R, Watanabe T, Morishita Y et al. Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002; 21: 2493-2503.
13. Yamaguchi N, Oyama T, Ito E et al. NOTCH3 signaling pathway plays crucial roles in proliferation of ErbB2-negative human breast cancer cells. Cancer Res 2008; 68: 1881-1888.
14. Charafe-Jauffret E, Ginestier C, Monville F et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006;25: 2273-2284.
15. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10:515-527.
16. Annunziata CM, Davis RE, Demchenko Y et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-130.
17. Keats JJ, Fonseca R, Chesi M et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007; 12:131-144.
18. Dhawan P, Su Y, Thu YM et al. The lymphotoxin-Β receptor is an upstream activator of NF-κB-mediated transcription in melanoma cells. J Biol Chem 2008; 283: 15399-408.
19. Saitoh Y, Yamamoto N, Dewan MZ et al. Overexpressed NF-κB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 2008; 111: 5118-5129.
20. Liao G, Zhang M, Harhaj EW et al. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004; 279: 26 243-250.
21. Fata JE, Kong YY, Li J et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103: 41-50.
22. Nishimura T, Koike R, Miyasaka M. Mammary glands of Aly mice:developmental changes and lactation-related expression of specific proteins, α-casein, GLyCAM-1 and MAdCAM-1. Am J Reprod Immunol 2000; 43:351-358.
23. Cao Y, Bonizzi G, Seagroves TN et al. IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001; 107: 763-775.
24. Liu S, Ginestier C, Charafe-Jauffret E et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008; 105: 1680-1685.
25. Furuta S, Jiang X, Gu B et al. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci USA 2005; 102: 9176-9181.
26. Sting J, Caldas C. Molecular heterogeniety of breast carcinomas and the cancer stem hypothesis. Nat Rev Cancer 2007; 7: 791-799.
27. Cao Y, Luo JL, Karin M. IκB kinase α activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA 2007; 104: 15852-15857.
28. Liu M, Ju X, Willmarth NE et al. Nuclear factor-κB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. Am J Pathol 2009; 174: 1910-1920.
29. Bertrand MJ, Milutinovic S, Dickson KM et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
30. Mahoney DJ, Cheung HH, Mrad RL et al. Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation. Proc Natl Acad Sci USA 2008; 105: 11778-17783.
31. Varfolomeev E, Goncharov T, Fedorova AV et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFα)-induced NF-κB activation. J Biol Chem 2008; 283: 24295-24299.
32. Kishore N, Sommers C, Mathialagan S et al. A selective IKK-2 inhibitor blocks NF-κB-dependent gene expression in interleukin-1Β-stimulated synovial fibroblasts. J Biol Chem 2003; 278: 32861-32871.
33. Lee H, Herrmann A, Deng JH et al. Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 2009; 15: 283-293.
34. Honeth G, Bendahl PO, Ringner M et al. The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008; 10: R53.
35. Ben-Porath I, Thomson MW, Carey VJ et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.Nat Genet 2008; 40: 499-507.